Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant setting for early-stage non-small-cell lung cancer, according to researchers at MD Anderson Cancer Center.
By improving hospital care pathways, researchers from MD Anderson Cancer Center successfully reduced inpatient opioid use by 50% after pancreatic cancer surgery and cut the median opioid prescription volumes at discharge to zero.
Researchers with the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine and four other institutions have developed a molecular test to identify the presence of brain tumors by measuring abnormal genetic material shed by tumors and circulating in cerebrospinal fluid.
Patients with acute myeloid leukemia who received vitamin C and D supplements while undergoing intensive chemotherapy had lower rates of complications, such as infections, bleeding, and inflammation, when compared with similar, previously treated patients who did not receive these supplements.
A team of scientists at VCU Massey Cancer Center discovered a previously unknown interaction between proteins that is responsible for supplying energy to tumor cells and could hold significant implications for the development of future treatments for colon cancer.
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are part of an international team of scientists who identified mechanisms by which some multiple myelomas become resistant to initially effective T-cell therapies.
A study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other top-tier cancer centers highlights the vital role that the immune system plays in determining the duration of patients’ remission from multiple myeloma.
Gene therapy that induces the body to create microRNA-22, or miR-22, a naturally occurring molecule, successfully treated mice with hepatocellular carcinoma in a study at the UC Davis Comprehensive Cancer Center. The miR-22 treatment also reduced liver inflammation and produced better survival outcomes compared to the FDA-approved liver cancer treatment lenvatinib.
Scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus. In a paper published in the journal mBio, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus. In evaluating EBVaGC’s epigenetics—the series of biological signals associated with the genome that determines whether a given gene is expressed—the Tempera lab highlights a target that could advance as a future treatment for this type of cancer.
NIH is planning to release a comprehensive dataset that standardizes genomic, proteomic, imaging, and clinical data from individual studies of more than 1,000 tumors across 10 cancer types.
